Jazz Pharma’s sleep disorder treatment gets FDA nod


FILE PHOTO: The headquarters of the U.S. Food and Drug Administration (FDA) is seen in Silver Spring, Maryland November 4, 2009. REUTERS/Jason Reed/File Photo

(Reuters) – The U.S. Food and Drug Administration approved Jazz Pharmaceuticals Plc’s treatment for patients with a form of sleep disorder, the company said on Wednesday.

The drug, solriamfetol, will treat excessive sleepiness in adult patients with narcolepsy or obstructive sleep apnea (OSA).

The decision is a big win for the drugmaker whose patents covering its blockbuster narcolepsy drug, Xyrem, was declared invalid by a U.S. appeals court in July.

Reporting by Aakash Jagadeesh Babu and Supriya Roy in Bengaluru; Editing by Richard Chang

Leave a Reply

Your email address will not be published. Required fields are marked *